Granted Patent B2

US 12,466,884 · App. 17/257,820 · Granted Nov 11, 2025

Inventors: Zhengjian Zhang (Albany, CA); Yang Li (Mountain View, CA); Wen-Chen Yeh (Belmont, CA); Tom Zhiye Yuan (Union City, CA); Helene Baribault (Redwood City, CA); Kuo-Pao Lai (South San Francisco, CA)

Assignee: Surrozen Operating, Inc.

C07K16/28A61P1/16C07K14/47C07K2317/565C07K2317/622C07K2319/81

Abstract

Claims (19)

1 . A tissue-specific Wnt (“Wingless-related integration site” or “Wingless and Int-1” or “Wingless-Int”) signal enhancing molecule, or a pharmaceutically acceptable salt thereof, comprising a first domain that specifically binds one or more transmembrane E3 ubiquitin ligases selected from Zinc and Ring Finger 3 (ZNRF3) and Ring Finger Protein 43 (RNF43), and a second domain that specifically binds asialoglycoprotein receptor 1 (ASGR1), wherein:

(a) the first domain comprises two R-spondin 2 polypeptides, or fragments thereof, each comprising the furin I domain of the R-spondin 2 polypeptide, wherein the R-spondin 2 polypeptides comprise amino acid substitutions at amino acids corresponding to F105 and F109 of the human R-spondin 2 of SEQ ID NO: 2; and/or

(b) the second domain comprises an antibody or antigen-binding fragment thereof comprising:

(i) a polypeptide comprising a heavy chain variable region comprising SEQ ID NO: 299; and

(ii) a polypeptide comprising a light chain variable region comprising SEQ ID NO: 298.

2 . The molecule of claim 1 , wherein the molecule is a liver-specific Wnt signal enhancing molecule.

3 . The molecule of claim 1 , wherein the molecule comprises a fusion protein, wherein the fusion protein comprises one of the two R-spondin 2 polypeptides, or fragments thereof, of the first domain, and the polypeptide comprising the heavy chain variable region of the second domain or the polypeptide comprising the light chain variable region of the second domain, optionally linked via a linker moiety.

4 . A nucleic acid sequence encoding for a polypeptide of the molecule of claim 1 .

5 . A pharmaceutical composition comprising:

a) an effective amount of the molecule of claim 1 ; and

b) a pharmaceutically acceptable diluent, adjuvant or carrier.

6 . The pharmaceutical composition of claim 5 , comprising the effective amount of the molecule of claim 1 and an effective amount of a Wnt polypeptide, a Norrin polypeptide, or a Wnt signaling agonist molecule.

7 . A method for increasing Wnt (“Wingless-related integration site” or “Wingless and Int-1” or “Wingless-Int”) signaling in a target tissue, comprising contacting the target tissue with:

a) the molecule of claim 1 , wherein the second domain specifically binds a cell-specific surface molecule on the target tissue, and wherein the molecule of claim 1 binds the target tissue and sequesters or increases endocytosis of one or more transmembrane E3 ubiquitin ligases selected from Zinc and Ring Finger 3 (ZNRF3) and Ring Finger Protein 43 (RNF43) in the target tissue; and/or

b) a Wnt polypeptide, a Norrin polypeptide, or a Wnt signaling agonist molecule; a nucleic acid sequence that encodes a Wnt polypeptide, a Norrin polypeptide, or a Wnt signaling agonist molecule; a vector comprising a nucleic acid sequence that encodes a Wnt polypeptide, a Norrin polypeptide, or a Wnt signaling agonist molecule; or a host cell comprising an expression vector comprising a nucleic acid sequence that encodes a Wnt polypeptide, a Norrin polypeptide, or a Wnt signaling agonist molecule; wherein the nucleic acid sequence that encodes the Wnt polypeptide, the Norrin polypeptide, or the Wnt signaling agonist molecule is optionally DNA or mRNA, optionally a modified mRNA.

8 . A method for treating a liver disease or liver condition in a subject in need thereof, wherein the liver disease or liver disorder is associated with reduced Wnt (“Wingless-related integration site” or “Wingless and Int-1” or “Wingless-Int”) signaling or would benefit from increased Wnt signaling, comprising providing to the subject an effective amount of the pharmaceutical composition of claim 5 , optionally wherein the molecule is the molecule of claim 2 .

9 . The method of claim 8 , comprising providing to the subject a pharmaceutical composition comprising an effective amount of the molecule of claim 1 and a pharmaceutical composition comprising an effective amount of a Wnt polypeptide, a Norrin polypeptide, or a Wnt signaling agonist molecule.

10 . A method for increasing liver to body weight ratio, promoting liver regeneration, increasing liver cell proliferation or mitosis, decreasing liver fibrosis, optionally following a chronic liver injury, increasing hepatocyte function, or decreasing coagulation time in liver, comprising providing to a subject an effective amount of the pharmaceutical composition of claim 5 , wherein the antibody or antigen-binding fragment thereof binds to an ASGR1.

11 . The molecule of claim 1 , wherein the amino acid substitutions are F105R and F109A.

Assignments (2)

Continuity (4)

References Cited (247)